{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Optimizing Risk Reduction in Patients with Acute Coronary Syndromes: Facing the Challenges

Activity Steps

2 Take Test 3Certificate

Purpose of Activity

To provide information on optimizing risk reduction in patients with acute coronary syndromes (ACS).

Learning Objectives

After completing this continuing education activity you will be able to:

Differentiate the pharmacologic profiles of oral antiplatelet drugs.
Interpret efficacy and safety data with oral antiplatelet therapies from acute coronary syndrome clinical trials.
Describe the importance of using low-dose aspirin in the long-term management of acute coronary syndrome patients.
Identify the duration of dual oral antiplatelet therapy elaborated in acute coronary syndrome clinical practice guidelines.
Summarize guideline recommendations for, and recognize therapies to reduce risk in, patients who have experienced an acute coronary syndrome.
Recognize effective hospital discharge transitions of care for patients who have experienced an acute coronary syndrome.

Disclosures

VoxMedia LLC is the co-provider of the continuing nursing education activity.

Dr. Bhatt has disclosed that he was/is the recipient of research grants from Amarin Corporation, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc., Ethicon, Hoffmann-La Roche Inc., Medtronic, Sanofi-Aventis, The Medicines Company.

Dr. Bhatt discusses unlabeled/unapproved uses of antithrombotic medications in his presentation.

Dr. Braun has disclosed that she was/is the recipient of research grants from the National Institutes of Health (NIH) and has received honorarium from the Preventive Cardiovascular Nurses Association (PCNA).

Dr. Sikkema has disclosed no potential conflicts of interest, financial or otherwise, related to this CE activity.

The CE planners have disclosed no potential conflicts of interest, financial or otherwise, related to this CE activity.

Lippincott Williams & Wilkins has identified and resolved any conflicts of interest regarding this educational activity.

Price: FREE

Credits:

ANCC 1.5 CH / 1.5 APH
DC - BON 1.5 CH
KY-BON 1.5 CH

Accreditation Statement

Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
--------------------------------------------------
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #50-1223. Your certificate is valid in all states.

Awarded Advanced Pharmacology Hours.

Planner

Test Code: NCNPACS0714

Published: Jul 2014

Expires: 12/31/2026

Required Passing Score: 11/15 (73%)

Authors: Lynne Braun, PhD, CNP, FAHA, FAAN; Deepak Bhatt, MD, MPH; Joanna Sikkema, DNP, MSN, ANP-BC, FAHA, FPCNA

Topics: Acute Coronary Syndrome , Advanced Pharmacology Hours , Atherosclerosis , Coronary Artery Disease , Heart Disease , Medications